Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chad Christopherson

Interventional Cardiology San Antonio, TX Medical Doctor

NPI 1154305365 CMS profile 97010

7390 Barlite Blvd, Ste 105, San Antonio, TX 78224

Open in the dashboard

General payments

$126,298

1,184 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$39,885 paid to institutions, not to them · program year 2025

Through program year 2025, Chad Christopherson of San Antonio, TX is reported in the CMS Open Payments database as having received $126,298 across 1,184 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $39,885 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $41,781 138
2024 General $26,880 148
2023 General $17,918 176
2022 General $17,294 206
2021 General $10,717 183
2020 General $3,624 118
2019 General $8,084 215

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chad Christopherson
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Chad Christopherson were reported at $41,781. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Chad Christopherson Interventional Cardiology median Middle half National median
2019 $8,084 $1,097 $329–$3,048 $163
2020 $3,624 $473 $161–$1,480 $114
2021 $10,717 $677 $233–$1,827 $132
2022 $17,294 $978 $333–$2,724 $149
2023 $17,918 $1,136 $382–$2,986 $160
2024 $26,880 $1,181 $395–$3,326 $164
2025 $41,781 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $39,521 44 payments
  2. Medtronic, Inc. $20,542 242 payments
  3. Penumbra, Inc. $19,819 94 payments
  4. Abbott Laboratories $13,603 247 payments
  5. Abiomed $5,834 59 payments
  6. Medtronic Vascular, Inc. $3,488 162 payments
  7. Edwards Lifesciences Corporation $2,896 40 payments
  8. International Rehabilitative Sciences, Inc $2,806 1 payment
  9. Cardiovascular Systems Inc. $2,273 31 payments
  10. Bard Peripheral Vascular, Inc. $1,744 24 payments
  11. Other $13,771 240 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $67,818 1,129 payments
  2. Long term medical supply or device loan $38,556 3 payments
  3. Travel and Lodging $13,869 44 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,300 5 payments
  5. Consulting Fee $500 1 payment
  6. Education $255 2 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Cv $30,000 1 payment
  2. Indigo System $18,780 84 payments
  3. COREVALVE EVOLUT R $9,886 99 payments
  4. Auryon Laser System 100-120 Vac Et $5,970 2 payments
  5. Impella $5,369 54 payments
  6. AURYON LASER SYSTEM 100-120 VAC Pad $3,534 39 payments
  7. RESOLUTE ONYX $2,831 16 payments
  8. RS 4i Plus Sequential Stimulator $2,806 1 payment
  9. OPTIS $2,243 18 payments
  10. COROFLOW $2,111 15 payments
  11. Other $44,904 876 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,843

Median for Interventional Cardiology: 2,236

Drug cost

$342,107

Median for Interventional Cardiology: $380,412

Branded share of claims

36.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 180 $204,781
Entresto Sacubitril/Valsartan Brand 79 $97,368
Xarelto Rivaroxaban Brand 17 $21,459
Ranolazine Er Ranolazine Brand 30 $3,759
Clopidogrel Clopidogrel Bisulfate Brand 262 $2,316
Carvedilol Generic 229 $2,070
Rosuvastatin Calcium Generic 53 $1,188
Atorvastatin Calcium Generic 118 $1,070
Metoprolol Succinate Generic 120 $1,050
Furosemide Generic 116 $648

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 124 billing codes

Paid by Medicare

$374,862

Of which drugs: $459

Medicare patients

540

Average age 75

Services billed

4,118

266 women, 274 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Diabetes 59%
Chronic kidney disease 55%
Arthritis 45%
Heart failure 42%
Atrial fibrillation 34%
Depression 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 20 1,563 $166
Injection, fentanyl citrate, 0.1 mg J3010 Office 21 32 $23
Injection, midazolam hydrochloride, per 1 mg J2250 Office 21 34 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
$73 — —
Arcalyst
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,184 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record